Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Wed, 26.06.2024
Eckert & Ziegler SE
Berlin, June 26, 2024. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year.
As in the previous year, the Annual General Meeting was held as an in-person event at Eckert & [ … ]
Tue, 25.06.2024
Eckert & Ziegler SE
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra [ … ]
Tue, 25.06.2024
Eckert & Ziegler SE
Würzburg/Berlin, Germany, 25 June 2024. Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registra [ … ]
Wed, 19.06.2024
Eckert & Ziegler SE
June 19, 2024 – Berlin, Germany and Řež, Czech Republic – Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”), announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated [ … ]
Fri, 31.05.2024
Eckert & Ziegler SE
BOSTON, Mass., May 31, 2024 – Eckert & Ziegler reports about the successful completion of the 2nd annual Boston Radionuclide Theranostics Forum, reaffirming its pivotal role in the field of radiopharmaceuticals. Building on the momentum of last year's inaugural event, the Forum once again brought together leading experts, potential and existing [ … ]
Fri, 24.05.2024
Eckert & Ziegler SE
Berlin, 24 May 2024. Eckert & Ziegler SE (ISIN DE0005659700) was honored with the “Best Managed Companies Award” at an award ceremony in Frankfurt am Main on May 23, 2024. With this award, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Federation of German Industries (Bundesverband der Deutschen Industrie e.V.) recognize outstand [ … ]
Tue, 14.05.2024
Eckert & Ziegler SE
1st Quarter 2024:
Sales of € 67.6 million (previous year: € 57.9 million)
EBIT before special items of € 15.0 million (previous year: € 10.6 million)
Net income € 8.5 million (previous year: € 4.7 million)
Forecast FY 2024:
Sales of just under € 265 Mio. (confirmed)
EBIT before special items of around € 50 million (confirmed)
Berlin, 14 May 2 [ … ]
Mon, 22.04.2024
Eckert & Ziegler SE
1st Quarter 2024:
Sales of EUR 67.6 million (previous year: EUR 57.9 million)
EBIT before special items of EUR 15.0 million (previous year: EUR 10.7 million)
Net income for the year of EUR 8.5 million (previous year: EUR 4.7 million)
Forecast FY 2024:
Sales of just under 265 million EUR (confirmed)
EBIT before special items of around EUR 50 mi [ … ]
Mon, 22.04.2024
Eckert & Ziegler SE
1st Quarter 2024:
Sales of EUR 67.6 million (previous year: EUR 57.9 million)
EBIT before special items of EUR 15.0 million (previous year: EUR 10.7 million)
Net income for the year of EUR 8.5 million (previous year: EUR 4.7 million)
Forecast FY 2024:
Sales of just under 265 million EUR (confirmed)
EBIT before special items of around EUR 50 mi [ … ]
Fri, 22.03.2024
Eckert & Ziegler SE
Berlin, March 22, 2024 - Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million correspon [ … ]